PreclinicalEvaluation of a Novel [ 177 Lu]Lu-Labeled PSMA/FAP Bispecific Radioligand for Prostate Cancer (EANM 2026) - Sep 29, 2026 - Abstract #EP-0164; "[177Lu]Lu-PSFA-1 demonstrated high radiochemical purity, excellent stability, strong affinity for both PSMA and FAP, and favorable tumor-specific retention in prostate cancer models. Compared with [177Lu]Lu-PSMA-617, this dual-targeting radioligand achieved higher tumor uptake and superior antitumor efficacy. These findings support further preclinical development of [177Lu]Lu-PSFA-1 as a promising candidate for radioligand therapy of heterogeneous tumors."
Bispecific • Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FAP
|
|
R. Xue 1; X. Wang 2; G. Wang 3; J. Cui 1; X. Wen 1; S. Geng 1; Y. Liu 4; B. Xu 4
|